ATE431359T1 - Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie - Google Patents

Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie

Info

Publication number: ATE431359T1
Authority: AT; Austria
Prior art keywords: molecular weight; weight markers; therapy; copolymers; copolymer
Prior art date: 1998-09-25

Application number

AT99949923T

Other languages

English (en)

Inventor

Alexander Gad

Dora Lis

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-25

Filing date

1999-09-24

Publication date

2009-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22285926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE431359(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-24 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

2009-05-15 Application granted granted Critical

2009-05-15 Publication of ATE431359T1 publication Critical patent/ATE431359T1/de

Links

229920001184 polypeptide Polymers 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
108010072051 Glatiramer Acetate Proteins 0.000 abstract 3
FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 abstract 3
229920001577 copolymer Polymers 0.000 abstract 3
229960003776 glatiramer acetate Drugs 0.000 abstract 3
230000004071 biological effect Effects 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
230000014759 maintenance of location Effects 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Pathology (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)

AT99949923T 1998-09-25 1999-09-24 Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie ATE431359T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10169398P	1998-09-25	1998-09-25
PCT/US1999/022402 WO2000018794A1 (en)	1998-09-25	1999-09-24	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use

Publications (1)

Publication Number	Publication Date
ATE431359T1 true ATE431359T1 (de)	2009-05-15

Family

ID=22285926

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT99949923T ATE431359T1 (de)	1998-09-25	1999-09-24	Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
AT09004306T ATE516297T1 (de)	1998-09-25	1999-09-24	Mit copolymer 1 verwandte polypeptide zur verwendung als molekulargewichtsmarker und zur therapeutischen verwendung

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT09004306T ATE516297T1 (de)	1998-09-25	1999-09-24	Mit copolymer 1 verwandte polypeptide zur verwendung als molekulargewichtsmarker und zur therapeutischen verwendung

Country Status (17)

Country	Link
EP (3)	EP2090583B1 (de)
JP (2)	JP4629229B2 (de)
AT (2)	ATE431359T1 (de)
AU (1)	AU757413B2 (de)
CA (2)	CA2343929C (de)
CY (3)	CY1110490T1 (de)
DE (2)	DE09004306T1 (de)
DK (3)	DK1115743T3 (de)
ES (3)	ES2327301T3 (de)
HU (3)	HU229289B1 (de)
IL (4)	IL142116A0 (de)
NO (2)	NO329877B1 (de)
NZ (1)	NZ511020A (de)
PT (3)	PT2239269E (de)
SI (1)	SI1115743T1 (de)
WO (1)	WO2000018794A1 (de)
ZA (1)	ZA200102269B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2527760T3 (es)	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005250A1 (en)	1998-07-23	2000-02-03	Yeda Research And Development Co., Ltd	Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
US6800287B2 (en)	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ZA200206457B (en)	2000-02-18	2003-08-13	Yeda Res & Dev	Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en)	2000-06-05	2002-06-20	Yong V. Wee	Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
AU6887101A (en) *	2000-06-20	2002-01-02	Caprion Pharmaceuticals, Inc.	Copolymers and methods of treating prion-related diseases
WO2002076503A1 (en)	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
US20040037828A1 (en) *	2002-07-09	2004-02-26	Bar-Ilan University	Methods and pharmaceutical compositions for healing wounds
JP5010798B2 (ja) *	2001-10-03	2012-08-29	プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ	自己免疫疾患を抑制するためのコポリマー、及びその使用方法
CA2469393C (en)	2001-12-04	2010-05-25	Teva Pharmaceutical Industries, Ltd.	Processes for the measurement of the potency of glatiramer acetate
NZ569331A (en)	2003-01-21	2010-08-27	Yeda Res & Dev	COP 1 for treatment of inflammatory bowel diseases
DK1651161T3 (da)	2003-08-07	2012-01-30	Healor Ltd	Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
RU2006134701A (ru) *	2004-03-01	2008-04-10	Пептиммьюн	Способы и композиции для лечения аутоиммунных заболеваний
US7655221B2 (en)	2004-05-07	2010-02-02	Peptimmune, Inc.	Methods of treating disease with random copolymers
DK1797109T3 (en)	2004-09-09	2016-04-11	Yeda Res & Dev	MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
US7858337B2 (en)	2007-03-08	2010-12-28	Novartis Ag	Process for the manufacture of a composite material
SG10201405806SA (en)	2009-08-20	2014-11-27	Yeda Res & Dev	Low Frequency Glatiramer Acetate Therapy
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en)	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
ES2602977T3 (es)	2010-10-11	2017-02-23	Teva Pharmaceutical Industries Ltd.	Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
WO2012123959A2 (en)	2011-02-14	2012-09-20	Usv Limited	Copolymer-1, process for preparation and analytical methods thereof
AU2012323345A1 (en)	2011-10-10	2014-05-22	Teva Pharmaceutical Industries Ltd.	Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
MX2015004563A (es)	2012-10-10	2015-07-14	Teva Pharma	Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
CN104098655B (zh) *	2013-04-09	2018-01-30	深圳翰宇药业股份有限公司	用于合成醋酸格拉替雷的质谱内标的多肽
UY35790A (es)	2013-10-21	2015-05-29	Teva Pharma	Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105218646B (zh) *	2014-06-24	2018-09-21	深圳翰宇药业股份有限公司	一种用于检测醋酸格拉替雷样本的uplc方法
US9155775B1 (en)	2015-01-28	2015-10-13	Teva Pharmaceutical Industries, Ltd.	Process for manufacturing glatiramer acetate product
EP3603764B1 (de) *	2015-04-28	2022-03-30	Hybio Pharmaceutical Co., Ltd.	Hochleistungsflüssigchromatografieverfahren
ES2744179T3 (es)	2015-09-24	2020-02-24	Chemi Spa	Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh)	2016-08-31	2019-07-05	Mapi医药公司	包含醋酸格拉替雷的储库系统
BR112019017724A2 (pt)	2017-03-26	2020-03-31	Mapi Pharma Ltd.	Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2009996A1 (en) *	1989-02-17	1990-08-17	Kathleen S. Cook	Process for making genes encoding random polymers of amino acids
IL113812A (en) *	1994-05-24	2000-06-29	Yeda Res & Dev	Copolymer-1 pharmaceutical compositions containing it and its use

1999
- 1999-09-24 EP EP09004306A patent/EP2090583B1/de not_active Expired - Lifetime
- 1999-09-24 AT AT99949923T patent/ATE431359T1/de active
- 1999-09-24 DK DK99949923T patent/DK1115743T3/da active
- 1999-09-24 CA CA2343929A patent/CA2343929C/en not_active Expired - Lifetime
- 1999-09-24 PT PT101715530T patent/PT2239269E/pt unknown
- 1999-09-24 HU HU0103889A patent/HU229289B1/hu unknown
- 1999-09-24 EP EP99949923A patent/EP1115743B1/de not_active Expired - Lifetime
- 1999-09-24 ES ES99949923T patent/ES2327301T3/es not_active Expired - Lifetime
- 1999-09-24 DK DK10171553.0T patent/DK2239269T3/da active
- 1999-09-24 ES ES10171553T patent/ES2408706T3/es not_active Expired - Lifetime
- 1999-09-24 HU HU1300337A patent/HU229720B1/hu unknown
- 1999-09-24 EP EP10171553A patent/EP2239269B1/de not_active Expired - Lifetime
- 1999-09-24 CA CA2794705A patent/CA2794705C/en not_active Expired - Lifetime
- 1999-09-24 HU HU1300505A patent/HU229719B1/hu unknown
- 1999-09-24 DE DE09004306T patent/DE09004306T1/de active Pending
- 1999-09-24 WO PCT/US1999/022402 patent/WO2000018794A1/en not_active Ceased
- 1999-09-24 ES ES09004306T patent/ES2369642T3/es not_active Expired - Lifetime
- 1999-09-24 PT PT99949923T patent/PT1115743E/pt unknown
- 1999-09-24 IL IL14211699A patent/IL142116A0/xx unknown
- 1999-09-24 AU AU62695/99A patent/AU757413B2/en not_active Expired
- 1999-09-24 NZ NZ511020A patent/NZ511020A/xx not_active IP Right Cessation
- 1999-09-24 AT AT09004306T patent/ATE516297T1/de active
- 1999-09-24 DK DK09004306.8T patent/DK2090583T3/da active
- 1999-09-24 DE DE69940888T patent/DE69940888D1/de not_active Expired - Lifetime
- 1999-09-24 ZA ZA200102269A patent/ZA200102269B/en unknown
- 1999-09-24 SI SI9931035T patent/SI1115743T1/sl unknown
- 1999-09-24 PT PT09004306T patent/PT2090583E/pt unknown
- 1999-09-24 JP JP2000572252A patent/JP4629229B2/ja not_active Expired - Lifetime
2001
- 2001-03-20 IL IL142116A patent/IL142116A/en not_active IP Right Cessation
- 2001-03-21 NO NO20011441A patent/NO329877B1/no not_active IP Right Cessation
2009
- 2009-08-06 CY CY20091100835T patent/CY1110490T1/el unknown
2010
- 2010-03-25 NO NO20100442A patent/NO336685B1/no not_active IP Right Cessation
- 2010-06-23 JP JP2010142689A patent/JP4903886B2/ja not_active Expired - Lifetime
- 2010-11-07 IL IL209189A patent/IL209189A/en not_active IP Right Cessation
- 2010-11-07 IL IL209190A patent/IL209190A/en not_active IP Right Cessation
2011
- 2011-10-05 CY CY20111100947T patent/CY1112197T1/el unknown
2013
- 2013-04-15 CY CY20131100310T patent/CY1113932T1/el unknown

Also Published As

Publication number	Publication date
ES2369642T3 (es)	2011-12-02
JP2010271325A (ja)	2010-12-02
NO20100442L (no)	2001-05-25
HUP0103889A2 (hu)	2002-03-28
NO20011441D0 (no)	2001-03-21
DE69940888D1 (de)	2009-06-25
HU229719B1 (en)	2014-05-28
WO2000018794A1 (en)	2000-04-06
EP2090583A1 (de)	2009-08-19
IL209189A (en)	2017-11-30
ES2327301T3 (es)	2009-10-27
PT1115743E (pt)	2009-07-07
HK1040521A1 (en)	2002-06-14
DK1115743T3 (da)	2009-07-27
NO329877B1 (no)	2011-01-17
PT2239269E (pt)	2013-04-09
EP1115743B1 (de)	2009-05-13
NO20011441L (no)	2001-05-25
CY1110490T1 (el)	2015-04-29
PT2090583E (pt)	2011-09-14
DE09004306T1 (de)	2010-12-09
HK1149279A1 (en)	2011-09-30
AU6269599A (en)	2000-04-17
CA2343929A1 (en)	2000-04-06
HU229289B1 (en)	2013-10-28
IL209190A0 (en)	2011-01-31
AU757413B2 (en)	2003-02-20
EP2239269A1 (de)	2010-10-13
ZA200102269B (en)	2002-03-19
NZ511020A (en)	2003-06-30
JP4903886B2 (ja)	2012-03-28
SI1115743T1 (sl)	2010-01-29
IL209190A (en)	2017-11-30
EP2239269B1 (de)	2013-01-16
IL209189A0 (en)	2011-01-31
HK1133021A1 (en)	2010-03-12
CY1112197T1 (el)	2015-12-09
HU229720B1 (en)	2014-05-28
JP2002525378A (ja)	2002-08-13
ES2408706T3 (es)	2013-06-21
IL142116A0 (en)	2002-03-10
CA2343929C (en)	2013-01-29
CA2794705A1 (en)	2000-04-06
CA2794705C (en)	2017-07-18
DK2239269T3 (da)	2013-04-29
ATE516297T1 (de)	2011-07-15
EP2090583B1 (de)	2011-07-13
EP1115743A4 (de)	2005-04-27
JP4629229B2 (ja)	2011-02-09
HUP0103889A3 (en)	2004-03-01
CY1113932T1 (el)	2016-07-27
EP1115743A1 (de)	2001-07-18
DK2090583T3 (da)	2011-09-12
IL142116A (en)	2010-12-30
NO336685B1 (no)	2015-10-19

Legal Events

Date

Code

Title

Description

2009-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1115743

Country of ref document: EP

Publication	Publication Date	Title
DE69940888D1 (de)	2009-06-25	Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
DK0397633T3 (da)	1996-01-02	Fibronectinbindende protein samt fremstilling deraf
ATE529444T1 (de)	2011-11-15	Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
TR200001709T2 (tr)	2001-03-21	Yeni neisseria meningitids yüzey proteini
NZ263344A (en)	1997-08-22	Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use
ATE226634T1 (de)	2002-11-15	Fibronektin bindendes protein
EE05497B1 (et)	2011-12-15	Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
NO882380L (no)	1988-12-02	Fibfonektin-bindende protein, samt fremstilling derav.
FI893681A0 (fi)	1989-08-03	N-2,3-butadienyltri- och tetra-aminoalkanderivat.
ATE271125T1 (de)	2004-07-15	Neuartige tyrosinkinase
ATE312179T1 (de)	2005-12-15	Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DK0870036T3 (da)	2008-11-24	Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
DE68906167D1 (de)	1993-06-03	Zusammensetzung zur erkennung von paradontalen krankheiten.
ATE242883T1 (de)	2003-06-15	Verfahren zur bestimmung von blutgerinnungsfaktoren viii und ix
DE68902792D1 (de)	1992-10-15	Mittel zur kosmetischen oder pharmazeutischen verwendung.
ATE198218T1 (de)	2001-01-15	Htfiiia gen